I
158.35
4.18 (2.71%)
| Previous Close | 154.17 |
| Open | 157.69 |
| Volume | 1,314,802 |
| Avg. Volume (3M) | 1,200,173 |
| Market Cap | 10,968,060,928 |
| Price / Earnings (TTM) | 37.00 |
| Price / Earnings (Forward) | 24.57 |
| Price / Sales | 3.77 |
| Price / Book | 8.19 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | 18.29% |
| Operating Margin (TTM) | 15.61% |
| Diluted EPS (TTM) | 5.54 |
| Quarterly Revenue Growth (YOY) | 28.80% |
| Quarterly Earnings Growth (YOY) | -31.30% |
| Total Debt/Equity (MRQ) | 131.40% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | 406.50 M |
| Levered Free Cash Flow (TTM) | 84.25 M |
| Return on Assets (TTM) | 6.94% |
| Return on Equity (TTM) | 37.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Insulet Corporation | Bearish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 102.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 435.00 (Canaccord Genuity, 174.71%) | Buy |
| Median | 340.00 (114.71%) | |
| Low | 300.00 (Oppenheimer, 89.45%) | Buy |
| Average | 350.90 (121.60%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 248.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 338.00 (113.45%) | Buy | 238.82 |
| 19 Feb 2026 | 345.00 (117.87%) | Buy | 249.10 | |
| Bernstein | 19 Feb 2026 | 330.00 (108.40%) | Buy | 249.10 |
| Canaccord Genuity | 19 Feb 2026 | 435.00 (174.71%) | Buy | 249.10 |
| Evercore ISI Group | 19 Feb 2026 | 340.00 (114.71%) | Buy | 249.10 |
| Goldman Sachs | 19 Feb 2026 | 326.00 (105.87%) | Buy | 249.10 |
| JP Morgan | 19 Feb 2026 | 340.00 (114.71%) | Buy | 249.10 |
| Leerink Partners | 19 Feb 2026 | 360.00 (127.34%) | Buy | 249.10 |
| Oppenheimer | 19 Feb 2026 | 300.00 (89.45%) | Buy | 249.10 |
| Truist Securities | 19 Feb 2026 | 360.00 (127.34%) | Buy | 249.10 |
| BTIG | 18 Feb 2026 | 380.00 (139.97%) | Buy | 258.07 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |